Seeking Alpha

Shares of Amarin (AMRN +2.1%) return to earth since spiking higher earlier this morning after...

Shares of Amarin (AMRN +2.1%) return to earth since spiking higher earlier this morning after its marketing website inadvertently circulated a report that Amarin's AMR101, or Vascepa, will be approved. The company acknowledged the error, saying that says no determination on AMR101 NDA has yet been made by the FDA, adding that information on the site was outdated and should not be relied on.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector